RECRUITING

Continuous Versus Intermittent cARdiac Electrical moNitorinG

Conditions

Torsades de Pointe Caused by Drug Long QT Syndrome

Quick Navigation

Study Overview

This clinical trial focuses on testing the efficacy of different digital interventions to promote re-engagement in cancer-related long-term follow-up care for adolescent and young adult (AYA) survivors of childhood cancer.

Description

The purpose of this study is to validate the continuous patch monitoring system to evaluate cardiac arrhythmias in patients receiving drugs that can cause cardiac complications and compare the continuous patch system with standard electrocardiograms (ECGs).

Official Title

Continuous Versus Intermittent cARdiac Electrical moNitorinG

Quick Facts

Study Start:2023-11-21

Study Completion:2025-12-31

Study Type:Not specified

Phase:Not Applicable

Enrollment:Not specified

Status:RECRUITING

Study ID

NCT04336644

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Ages Eligible for Study:18 Years

Sexes Eligible for Study:ALL

Accepts Healthy Volunteers:No

Standard Ages:ADULT, OLDER_ADULT

Inclusion Criteria	Exclusion Criteria
* Diagnosis of acute promyelocytic leukemia (APL) and being initiated on standard of care arsenic trioxide OR Diagnosis of solid tumor and being initiated on standard of care capecitabine (alone or as part of combination treatment) OR Diagnosis of solid tumor and being initiated on standard of care ribociclib (alone or as part of combination treatment) * At least 18 years of age. * No allergy to adhesive patches. * Able to understand and willing to sign an IRB-approved written informed consent document.	* Younger than 18 years of age * Allergy to adhesive patches

Inclusion Criteria

Exclusion Criteria

* Diagnosis of acute promyelocytic leukemia (APL) and being initiated on standard of care arsenic trioxide OR Diagnosis of solid tumor and being initiated on standard of care capecitabine (alone or as part of combination treatment) OR Diagnosis of solid tumor and being initiated on standard of care ribociclib (alone or as part of combination treatment)
* At least 18 years of age.
* No allergy to adhesive patches.
* Able to understand and willing to sign an IRB-approved written informed consent document.

* Younger than 18 years of age
* Allergy to adhesive patches

Contacts and Locations

Study Contact

Joshua D Mitchell, M.D., FACC

CONTACT

314-494-3124

jdmitchell@wustl.edu

Kaitlin Moore

CONTACT

314-273-0830

kaitlin.m.moore@wustl.edu

Principal Investigator

Joshua D Mitchell, M.D., FACC

PRINCIPAL_INVESTIGATOR

Washington University School of Medicine

Study Locations (Sites)

Washington University School of Medicine

Saint Louis, Missouri, 63110

United States

Collaborators and Investigators

Sponsor: Washington University School of Medicine

Joshua D Mitchell, M.D., FACC, PRINCIPAL_INVESTIGATOR, Washington University School of Medicine

Study Record Dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Registration Dates

Study Start Date2023-11-21

Study Completion Date2025-12-31

Study Record Updates

Study Start Date2023-11-21

Study Completion Date2025-12-31

Terms related to this study

Additional Relevant MeSH Terms

Torsades de Pointe Caused by Drug
Long QT Syndrome